In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis.

Abstract

Recently we demonstrated that in inflammatory bowel disease (IBD) macrophage-oxidative burst activity is increased and NADPH oxidase mRNA is induced. The herbal phenylethanoid acteoside isolated from Plantago lanceolata L. was shown to exhibit anti-oxidative potential. Using the dextran sulphate sodium (DSS)-induced colitis model, in this study we have assessed whether systemic application of acteoside affects colitis. Colitis was induced by DSS in Balb/c mice. Treatment with acteoside (120, 600 microg/mouse/day) was performed intraperitoneally. The colon lengths were determined. Colonic tissue was scored histologically (max. score 8) by a blinded investigator. T cells isolated from mesenteric lymph nodes (MLN) were stimulated with anti-CD3 antibody in the presence of interleukin (IL)-2 (final concentration 10 U/ml). After incubation for 24 h, IL-1beta, IL-6, IL-12 tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma levels in supernatants were analysed by the beadlyte cytokine detection system. Histological scoring of colonic tissue revealed that application of acteoside was followed by a significantly improved histological score. In acute colitis the histological score was 3.2 with acteoside versus 5.2 with phosphate-buffered saline (PBS) (P < 0.02). In chronic colitis both 120 microg (3.3 versus 5.2) or 600 microg acteoside (3.0 versus 5.2) significantly ameliorated colitis (both P < 0.02). Stimulated MLN from mice with chronic DSS-induced colitis treated with acteoside showed a significant down-regulation of IFN-gamma secretion (195 pg/ml with 600 microg acteoside versus 612 pg/ml with PBS, P < 0.02). Inhibition of oxidative burst activity with acteoside reduced mucosal tissue damage in DSS colitis and could be a therapeutic alternative for IBD treatment. Further studies of this agent are warranted.

• Authors: M Hausmann, F Obermeier, D H Paper, K Balan, N Dunger, K Menzel, W Falk, J Schoelmerich, H Herfarth, G Rogler
• Journal: Clinical and experimental immunology (Clin Exp Immunol) Vol. 148 Issue 2 Pg. 373-81 (May 2007) ISSN: 0009-9104 [Print] England
• PMID: 17437425 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antioxidants
• Cytokines
• Glucosides
• Inflammation Mediators
• Phenols
• acteoside
• Dextran Sulfate
• Peroxidase

Topics

• Acute Disease
• Animals
• Antioxidants (therapeutic use)
• Chronic Disease
• Colitis (chemically induced, drug therapy, immunology, pathology)
• Colon (immunology)
• Cytokines (metabolism)
• Dextran Sulfate
• Enzyme-Linked Immunosorbent Assay (methods)
• Female
• Glucosides (therapeutic use)
• Inflammation Mediators (metabolism)
• Intestinal Mucosa (immunology)
• Lymph Nodes (immunology)
• Macrophages (immunology)
• Mice
• Mice, Inbred BALB C
• Peroxidase (metabolism)
• Phenols (therapeutic use)
• Respiratory Burst (drug effects)
• Weight Loss (drug effects)